1. Impact of GGCX polymorphisms on warfarin doserequirements in atrial fibrillation patients
   Nian-Xin JIANG et al, 2017, TURKISH JOURNAL OF MEDICAL SCIENCES CrossRef
2. Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population
   Letícia C. Tavares et al, 2018, European Journal of Clinical Pharmacology CrossRef
3. Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients
   Suli Zhang et al, 2024, Pharmacogenetics and Genomics CrossRef
4. Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials
   Ting Yang et al, 2019, Journal of Clinical Pharmacy and Therapeutics CrossRef
5. Influence of Polymorphisms in CYP2C9 , VKORC1 , MDR1 and APOE Genes on the Warfarin Maintenance Dose in Brazilian Patients
   Emílio Itamar de Freitas Campos et al, 2023, Pharmacogenomics CrossRef
6. Pharmacogenetics of warfarin dosing in Chinese adults with nonvalvular atrial fibrillation
   Ye Zhu et al, 2023, European Journal of Clinical Pharmacology CrossRef
7. Warfarin Pharmacogenomics in Diverse Populations
   Justin B. Kaye et al, 2017, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy CrossRef
8. Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine
   Cristina Lucía Dávila-Fajardo et al, 2019, Genes CrossRef
9. GENETIC POLYMORPHISMS OF CYTOCHROME P450 2C9, VITAMIN K EPOXIDE-REDUCTASE SUBUNIT 1 AND WARFARIN DOSING IN PATIENTS WITH PERMANENT ATRIAL FIBRILLATION
   A O Rubanenko et al, 2016, Science and Innovations in Medicine CrossRef
10. Genotype-Guided Warfarin Therapy: Current Status
    Letícia C Tavares et al, 2018, Pharmacogenomics CrossRef
11. Ethnic Diversity and Warfarin Pharmacogenomics
    Innocent G. Asiimwe et al, 2022, Frontiers in Pharmacology CrossRef